卡瑞利珠单抗联合多西他赛卡铂新辅助治疗II-III期三阴性乳腺癌的随机临床试验
HELEN-Trio 011研究为多中心随机开放标签3期试验,纳入369例II-III期TNBC患者,比较卡瑞利珠单抗联合多西他赛+卡铂与单纯化疗的新辅助疗效。mITT人群352例中,联合组pCR率57.5% vs 45.4%,绝对差异12.2%(95%CI 1.4-22.9,单侧P=0.014)。3-4级治疗相关不良事件发生率24.9% vs 21.8%,无治疗相关死亡。
要点
- 卡瑞利珠单抗联合多西他赛+卡铂新辅助显著提高II-III期TNBC的pCR率
- 绝对pCR差异12.2%,安全性可控,未增加治疗相关死亡
- 为非蒽环类化疗联合免疫新辅助方案提供了随机3期证据
核心结论
- 在II-III期TNBC新辅助治疗中,卡瑞利珠单抗联合多西他赛+卡铂较单纯化疗显著提高pCR率,安全性可控。
研究设计与样本
- 多中心、随机、开放标签、3期试验,中国14家医院,2022年12月至2025年6月,入组369例,mITT人群352例。
- 入组标准为18-70岁女性、既往未治疗的II-III期TNBC,按2:1随机分组。
- 试验组接受6周期多西他赛(75 mg/m2)+卡铂(AUC=6)联合卡瑞利珠单抗(200 mg静脉第3天),对照组仅化疗。
- 主要终点为pCR(ypT0/Tis ypN0),在mITT人群(至少接受一剂研究治疗)中评估。
主要发现
- 联合组pCR率为57.5%(134/233),单纯化疗组为45.4%(54/119)。
- 绝对差异为12.2%(95%CI 1.4-22.9;单侧P=0.014)。
- 3-4级治疗相关不良事件发生率联合组24.9%(58/233),化疗组21.8%(26/119)。
- 未报告治疗相关死亡。
关键数值与推荐
- pCR定义为ypT0/Tis ypN0。
- 多西他赛剂量75 mg/m2,卡铂AUC=6,卡瑞利珠单抗200 mg静脉第3天,每周期6次。
- 主要终点pCR在mITT人群分析,绝对差异12.2%(95%CI 1.4-22.9;单侧P=0.014)。
临床怎么用
- 对于II-III期TNBC患者,可考虑卡瑞利珠单抗联合多西他赛+卡铂作为非蒽环类新辅助 chemoimmunotherapy 方案。
- 该方案安全性可控,需关注3-4级治疗相关不良事件。
- 该方案与当前标准化疗免疫方案的比较尚需进一步研究。
局限性
- 研究为开放标签设计,可能存在偏倚。
- 随访时间有限,未报告长期生存结局。
- 研究仅在中国进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemoimmunotherapy has become the standard-of-care for stage II-III triple-negative breast cancer (TNBC); however, anthracycline-containing regimens are associated with considerable toxicity. We evaluated camrelizumab combined with an anthracycline-free docetaxel-carboplatin regimen in this setting. PATIENTS AND METHODS: We performed a multicenter, randomized, open-label, phase 3 trial at 14 hospitals in China between December 2022 and June 2025. Eligible patients were women aged 18-70 years with previously untreated, stage II-III TNBC. Patients were randomized 2:1 to receive 6 cycles of neoadjuvant docetaxel (75 mg/m2) plus carboplatin (area under the curve [AUC]=6) on day 1, with or without camrelizumab (200 mg intravenously on day 3). The primary endpoint was pathological complete response (pCR), defined as ypT0/Tis ypN0, evaluated in the modified intention-to-treat (mITT) population (all patients who received at least one dose of study treatment). RESULTS: A total of 369 patients were enrolled, and 352 comprised the mITT population for efficacy analysis. The pCR rate was 57.5% (134/233) in the camrelizumab-chemotherapy group and 45.4% (54/119) in the chemotherapy-alone group, corresponding to an absolute difference of 12.2% (95% CI, 1.4 to 22.9; one-sided P=0.014). Grade 3-4 treatment-related adverse events occurred in 24.9% (58/233) in the camrelizumab-chemotherapy group and 21.8% (26/119) in the chemotherapy-alone group. No treatment-related deaths were reported. CONCLUSION: The addition of camrelizumab to neoadjuvant docetaxel plus carboplatin significantly increased the pCR rate in patients with stage II-III TNBC, with a manageable safety profile. This regimen represents a promising anthracycline-free strategy that warrants comparison with current standard chemoimmunotherapy .
引用
- Jiao D, Sun X, Qiao J, et al. Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. Ann Oncol. 2026. PMID: 42887596. doi:10.1016/j.annonc.2026.10.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。